Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 288

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Larocca, Alessandra, Cavallo, Federica, Bringhen, Sara, Di Raimondo, Francesco, Falanga, Anna, Evangelista, Andrea, Cavalli, Maide, Stanevsky, Anfisa, Corradini, Paolo, Pezzatti, Sara, Patriarca, Francesca, Cavo, Michele, Peccatori, Jacopo, Catalano, Lucio, Carella, Angelo Michele, Cafro, Anna Maria, Siniscalchi, Agostina, Crippa, Claudia, Petrucci, Maria Teresa, Yehuda, Dina Ben, Beggiato, Eloise, Di Toritto, Tommaso Caravita, Boccadoro, Mario, Nagler, Arnon, Palumbo, Antonio·2012·Blood
DOI 10.1182/blood-2011-03-344333
Open this paper in CoChat — free account

Abstract

Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE). This prospective, open-label, randomized substudy of a phase 3 trial compared the efficacy and safety of thromboprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in patients with newly diagnosed MM, treated with lenalidomide and low-dose dexamethasone induction and melphalan-prednisone-lenalidomide consolidation. Overall, 342 patients who did not have clinical indications or contraindications to antiplatelet or anticoagulant therapy were randomly assigned to receive ASA 100 mg/d (n = 176) or LMWH enoxaparin 40 mg/d (n = 166). The incidence of VTE was 2.27% in the ASA group and 1.20% in the LMWH group. Compared with LMWH, the absolute difference in the proportion of VTE was 1.07% (95% confidence interval, −1.69-3.83; P = .452) in the ASA group. Pulmonary embolism was observed in 1.70% of patients in the ASA group and none in the LMWH group. No arterial thrombosis, acute cardiovascular events, or sudden deaths were reported. No major hemorrhagic complications were reported. In previously untreated patients with MM receiving lenalidomide with a low thromboembolic risk, ASA could be an effective and less-expensive alternative to LMWH thromboprophylaxis. This study was registered at www.clinicaltrials.gov as #NCT00551928.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-03-344333

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 288

Metadata

Authors
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., Peccatori, J., Catalano, L., Carella, A. M., Cafro, A. M., Siniscalchi, A., Crippa, C., Petrucci, M. T., Yehuda, D. B., Beggiato, E., Di Toritto, T. C., Boccadoro, M., Nagler, A., & Palumbo, A.
Venue
Blood
Publisher
American Society of Hematology
Published
2012-01-26
Volume
119
Issue
4
Pages
933-939
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2011-03-344333
OpenAlex
W2026895719
Cited by
288
References
27
FWCI
21.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. https://app.cochat.ai/papers/10.1182/blood-2011-03-344333
The paper
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., Peccatori, J., Catalano, L., Carella, A. M., Cafro, A. M., Siniscalchi, A., Crippa, C., Petrucci, M. T., . . . Palumbo, A. (2012). Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. https://doi.org/10.1182/blood-2011-03-344333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.